Keros Therapeutics Inc (NASDAQ: KROS) is -26.03% lower on its value in year-to-date trading and has touched a low of $9.77 and a high of $73.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The KROS stock was last observed hovering at around $11.37 in the last trading session, with the day’s gains setting it 0.34%.
Currently trading at $11.71, the stock is -9.36% and -62.20% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.38 million and changing 2.99% at the moment leaves the stock -75.31% off its SMA200. KROS registered -79.93% loss for a year compared to 6-month loss of -77.20%. The firm has a 50-day simple moving average (SMA 50) of $31.948 and a 200-day simple moving average (SMA200) of $47.6685.
The stock witnessed a -28.68% gain in the last 1 month and extending the period to 3 months gives it a -80.72%, and is -2.58% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.55% over the week and 6.26% over the month.
Keros Therapeutics Inc (KROS) has around 136 employees, a market worth around $474.34M and $0.65M in sales. Profit margin for the company is -27890.94%. Distance from 52-week low is 19.80% and -83.96% from its 52-week high. The company has generated returns on investments over the last 12 months (-33.00%).
with sales reaching $37.32M over the same period.The EPS is expected to grow by 0.22% this year, but quarterly earnings will post 21,125.47% year-over-year. Quarterly sales are estimated to grow 25,996.63% in year-over-year returns.
245.0 institutions hold shares in Keros Therapeutics Inc (KROS), with institutional investors hold 102.29% of the company’s shares. The shares outstanding are 39.26M, and float is at 32.86M with Short Float at 12.23%. Institutions hold 100.20% of the Float.
The top institutional shareholder in the company is FMR LLC with over 4.72 million shares valued at $215.69 million. The investor’s holdings represent 16.0279 of the KROS Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 2.51 million shares valued at $114.86 million to account for 8.5348 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 1.76 million shares representing 5.967 and valued at over $80.3 million, while ALKEON CAPITAL MANAGEMENT LLC holds 5.4298 of the shares totaling 1.6 million with a market value of $73.07 million.
Keros Therapeutics Inc (KROS) Insider Activity
The most recent transaction is an insider sale by GORDON CARL L, the company’s Director. SEC filings show that GORDON CARL L sold 250,000 shares of the company’s common stock on Aug 13 ’24 at a price of $44.01 per share for a total of $11.0 million. Following the sale, the insider now owns 0.12 million shares.
Keros Therapeutics Inc disclosed in a document filed with the SEC on Aug 13 ’24 that ORBIMED ADVISORS LLC (Director) sold a total of 250,000 shares of the company’s common stock. The trade occurred on Aug 13 ’24 and was made at $44.01 per share for $11.0 million. Following the transaction, the insider now directly holds 0.12 million shares of the KROS stock.
Still, SEC filings show that on Aug 13 ’24, OrbiMed Genesis Master Fund, L (Shareholder) Proposed Sale 29,400 shares at an average price of $44.84 for $1.32 million. The insider now directly holds shares of Keros Therapeutics Inc (KROS).
